Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 174Neoplasm Metastasis 139Neoplasms 133Leukemia, Myeloid, Acute 127Colorectal Neoplasms 126Breast Neoplasms 113Melanoma 88Ovarian Neoplasms 87Prostatic Neoplasms 86Recurrence 84Multiple Myeloma 79Pancreatic Neoplasms 74Squamous Cell Carcinoma of Head and Neck 72Glioblastoma 71Lung Neoplasms 70Lymphoma, Non-Hodgkin 62Myelodysplastic Syndromes 60Triple Negative Breast Neoplasms 56Stomach Neoplasms 52Glioma 52Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Endometrial Neoplasms 47Carcinoma, Renal Cell 47Small Cell Lung Carcinoma 46Lymphoma, Large B-Cell, Diffuse 44Brain Neoplasms 43Carcinoma, Hepatocellular 41Sarcoma 39Advanced Solid Tumors 39Lymphoma, Follicular 38

Interventions

dapagliflozin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hyperinsulinism × 90 days × Clear all
NCT05989347 2026-05-22

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

Yale University

Phase 1 Recruiting
20 enrolled
Breast

Breast Neoplasms, Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡